News

Filter News By

Clear Filters

  1. CF Foundation Awards Funding for First-Ever Controlled Clinical Study of Phage Therapy in CF

    March 18, 2020

    The Cystic Fibrosis Foundation awarded up to $5 million to Armata Pharmaceuticals for the first-ever controlled clinical study of phage therapy in CF, reaffirming the Foundation’s commitment to advance innovative solutions to the growing challenge of antibiotic resistance.

  2. Update on COVID-19

    March 3, 2020

    As public health officials assess the risk of the coronavirus (COVID-19) on the overall population, the Cystic Fibrosis Foundation is evaluating its potential impact on people with cystic fibrosis.

  3. More than 200 Advocates Urge Congress for More Antibiotics During March on the Hill

    March 2, 2020

    More than 200 advocates gathered on Capitol Hill during the Cystic Fibrosis Foundation's 14th Annual March on the Hill, championing antibiotic research and development and other policy needs on behalf of people with CF.

  4. ICER Issues Draft Evidence Report for Assessment of Trikafta

    February 20, 2020

    The Institute for Clinical and Economic Review (ICER) recently posted a draft evidence report to outline their initial assessment of the clinical effectiveness and value of CFTR modulators, including elexacaftor/tezacaftor/ivacaftor (TrikaftaTM). The document is open for public comment through March 18.

    Topics:

  5. Cystic Fibrosis Foundation Supports Development of Non-Porcine Enzyme Therapy

    February 12, 2020

    The Cystic Fibrosis Foundation has entered into an agreement with Synspira Therapeutics Inc. to develop a non-porcine enzyme replacement therapy to offer an alternative to people with cystic fibrosis who cannot digest food properly.

  6. Choate Construction Named the Top 2019 National Corporate Team

    January 24, 2020

    Choate Construction's National Corporate Team raised over $670,000 for the Cystic Fibrosis Foundation in 2019, serving as a role model for corporations looking to integrate philanthropy into their business model.

    Topics:

  7. CF Foundation Awards Leading Research Organization Funding to Screen for Potential B. Cepacia Therapy

    January 14, 2020

    The Cystic Fibrosis Foundation awarded nearly $700,000 to Calibr, the drug discovery and development arm of Scripps Research, to screen for a compound that could be used to treat Burkholderia cepacia complex infections.

  8. Circuit Court Rules on ACA in Texas v. United States

    December 19, 2019

    On Dec. 18, the Fifth Circuit Court of the United States issued a decision in Texas v. United States, ruling the individual mandate unconstitutional but sending the case back down to the district court for further review about the fate of the entire Affordable Care Act.

    Topics:

  9. Foundation Announces 2020 Volunteer Leadership Conference Co-Chairs

    December 13, 2019

    Ray Poole and Julie Riedy to lead efforts in Washington, D.C., for volunteer conference, Until CF Stands for Cure Found.

    Topics:

  10. Cystic Fibrosis Foundation Is Exploring New CFTR Modulators

    October 24, 2019

    The Cystic Fibrosis Foundation announced today that it has licensed a compound to the biopharmaceutical company AbbVie to develop into a potential CFTR modulator treatment.

  11. CF Foundation Celebrates FDA Approval of Triple Combination

    October 21, 2019

    The U.S. Food and Drug Administration has approved the use of the triple-combination modulator elexacaftor/tezacaftor/ivacaftor (Trikafta™) for people with cystic fibrosis ages 12 and older who have at least one copy of the F508del mutation.

  12. Enterprise Therapeutics Awarded Up to $7M to Develop Mucus-Clearance Drug for People With CF

    October 15, 2019

    The Cystic Fibrosis Foundation has awarded up to $7 million to Enterprise Therapeutics to develop a compound that targets a non-CFTR chloride channel in lung cells. If successful, the drug could help mucus become more hydrated and easier to clear from the lungs of all people with CF, regardless of their CFTR mutations.

    Topics:

More Posts View All Posts

Related Content

Follow Us On